CytomX Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sean A. McCarthy
- Full Time Employees
- 119
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 151 Oyster Point Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Oct 8, 2015
- CIK
- 0001501989
- Website
- cytomx.com
- Similar Companies
- Business
- CytomX Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company specializing in the development of novel conditionally activated biologics through its proprietary Probody® therapeutic platform. The company’s pipeline includes a range of therapeutics targeting cancer, such as antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators including cytokines, designed to be activated specifically within the tumor microenvironment to enhance efficacy while minimizing systemic toxicity. CytomX’s main products and services encompass the development of masked biologics that address solid tumors by leveraging its Probody technology to improve tumor targeting and immune activation. The company operates primarily in the United States from its headquarters in South San Francisco, California, and collaborates with global biopharmaceutical partners including Astellas, Moderna, Amgen, Bristol Myers Squibb, and Regeneron. Founded in 2008, CytomX has recently advanced key clinical-stage programs such as CX-2051, a masked EpCAM-targeting ADC with a novel topoisomerase-1 payload focused on advanced colorectal cancer, and CX-801, a PROBODY interferon-alpha 2b cytokine undergoing trials in metastatic melanoma and other solid tumors. Significant 2024-2025 developments include initiating Phase 1 studies for these programs and entering strategic partnerships with Astellas for T-cell engager bispecific therapeutics and Moderna for mRNA-based conditionally activated therapies in oncology. The company also established a clinical collaboration with Merck to evaluate CX-801 in combination with the anti-PD-1 therapy Keytruda (pembrolizumab). Financially, CytomX reported $143.6 million in cash, cash equivalents, and investments as of Q3 2025, supporting ongoing clinical development and extending its cash runway into 2026 following a corporate restructuring. These operational and strategic advances reflect CytomX’s focus on developing next-generation immuno-oncology therapies that improve safety and effectiveness in cancer treatment.
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
CytomX Therapeutics: Cashed Up With Catalysts Ahead
CytomX Therapeutics to Present at Upcoming June Investor Conferences
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Small Cap or Megacap: Which Healthcare Stock Is Right for You?
Stock Traders Buy High Volume of CytomX Therapeutics Put Options (NASDAQ:CTMX)
CytomX Therapeutics (NASDAQ:CTMX) & Adagene (NASDAQ:ADAG) Financial Comparison
Assenagon Asset Management S.A. Sells 137,271 Shares of CytomX Therapeutics, Inc. $CTMX
CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade
Why Is CytomX Therapeutics Stock Falling On Wednesday?
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
Boothbay Fund Management LLC Buys Shares of 1,237,057 CytomX Therapeutics, Inc. $CTMX
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data